Evolutionary rescue by aneuploidy in tumors exposed to anti-cancer drugs

preprint OA: closed
Full text JSON View at publisher
Full text 1,903 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Evolutionary rescue happens when a population survives a sudden environmental change that initially causes the population to decline toward extinction. A prime example of evolutionary rescue is the ability of cancer to survive exposure to treatment. One evolutionary mechanism by which a population of cancer cells can adapt to chemotherapy is aneuploidy. Aneuploid cancer cells can be fitter in an environment altered by anti-cancer drugs, e.g., because aneuploidy disrupts the pathways usually targeted by the drugs. Indeed, aneuploidy is highly prevalent in tumors, and some anti-cancer drugs fight cancer by increasing chromosomal instability. Here, we model the impact of aneuploidy on the fate of a population of cancer cells. We use multi-type branching processes to approximate the probability that a tumor survives drug treatment as a function of the initial tumor size, the rates at which aneuploidy and other beneficial mutations occur, and the growth rates of the drug-sensitive and drug-resistant cells. Additionally, we investigate the effect of the pre-existent aneuploid cells on the probability of evolutionary rescue. Finally, we estimate the tumor’s mean recurrence time to revert to its initial size following treatment and evolutionary rescue. We propose that aneuploidy can play an essential role in the relapse of smaller secondary tumors. DOI https://doi.org/10.32942/X26K8C Subjects Ecology and Evolutionary Biology, Evolution, Genetics, Life Sciences

Keywords

aneuploidy, evolutionary model, adaptive evolution, Cancer, drug resistance, chromosome instability Dates Published: 2024-07-31 14:22 License CC-By Attribution-ShareAlike 4.0 International Additional Metadata Conflict of interest statement: None Data and Code Availability Statement: Not applicable Language: English

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00